dc.date.accessioned | 2023-03-03T18:00:26Z | |
dc.date.available | 2023-03-03T18:00:26Z | |
dc.date.created | 2022-05-05T09:14:49Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Wolowczyk, Camilla Neckmann, Ulrike Aure, Miriam Ragle Hall, Martina Johannessen, Bjarne Zhao, Sen Skotheim, Rolf I. Andersen, Sonja Benedikte Zwiggelaar, Rosalie Theda Margien Steigedal, Tonje S. Lingjærde, Ole Christian Sahlberg, Kristine Kleivi Almaas, Eivind Bjørkøy, Geir . NRF2 drives an oxidative stress response predictive of breast cancer. Free Radical Biology & Medicine. 2022, 184, 170-184 | |
dc.identifier.uri | http://hdl.handle.net/10852/100651 | |
dc.description.abstract | Many breast cancer patients are diagnosed with small, well-differentiated, hormone receptor-positive tumors. Risk of relapse is not easily identified in these patients, resulting in overtreatment. To identify metastasis-related gene expression patterns, we compared the transcriptomes of the non-metastatic 67NR and metastatic 66cl4 cell lines from the murine 4T1 mammary tumor model. The transcription factor nuclear factor, erythroid 2-like 2 (NRF2, encoded by NFE2L2) was constitutively activated in the metastatic cells and tumors, and correspondingly a subset of established NRF2-regulated genes was also upregulated. Depletion of NRF2 increased basal levels of reactive oxygen species (ROS) and severely reduced ability to form primary tumors and lung metastases. Consistently, a set of NRF2-controlled genes was elevated in breast cancer biopsies. Sixteen of these were combined into a gene expression signature that significantly improves the PAM50 ROR score, and is an independent, strong predictor of prognosis, even in hormone receptor-positive tumors. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | NRF2 drives an oxidative stress response predictive of breast cancer | |
dc.title.alternative | ENEngelskEnglishNRF2 drives an oxidative stress response predictive of breast cancer | |
dc.type | Journal article | |
dc.creator.author | Wolowczyk, Camilla | |
dc.creator.author | Neckmann, Ulrike | |
dc.creator.author | Aure, Miriam Ragle | |
dc.creator.author | Hall, Martina | |
dc.creator.author | Johannessen, Bjarne | |
dc.creator.author | Zhao, Sen | |
dc.creator.author | Skotheim, Rolf I. | |
dc.creator.author | Andersen, Sonja Benedikte | |
dc.creator.author | Zwiggelaar, Rosalie Theda Margien | |
dc.creator.author | Steigedal, Tonje S. | |
dc.creator.author | Lingjærde, Ole Christian | |
dc.creator.author | Sahlberg, Kristine Kleivi | |
dc.creator.author | Almaas, Eivind | |
dc.creator.author | Bjørkøy, Geir | |
cristin.unitcode | 185,53,18,10 | |
cristin.unitname | Avdeling for medisinsk genetikk | |
cristin.ispublished | true | |
cristin.fulltext | preprint | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2021634 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Free Radical Biology & Medicine&rft.volume=184&rft.spage=170&rft.date=2022 | |
dc.identifier.jtitle | Free Radical Biology & Medicine | |
dc.identifier.volume | 184 | |
dc.identifier.startpage | 170 | |
dc.identifier.endpage | 184 | |
dc.identifier.doi | https://doi.org/10.1016/j.freeradbiomed.2022.03.029 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0891-5849 | |
dc.type.version | PublishedVersion | |
dc.relation.project | EC/HEU/223255 | |